Sign In | Join Free | My tjskl.org.cn
China Walvax Biotechnology Co., Ltd. logo
Walvax Biotechnology Co., Ltd.
Help Everyone Live a Healthy Life!
Verified Supplier

1 Years

Home > Meningococcal ACYW-135 Vaccine >

Walvax 1 Dose / Vial Childhood Meningococcal ACYW-135 Vaccine

Walvax Biotechnology Co., Ltd.
Trust Seal
Verified Supplier
Credit Check
Supplier Assessment

Walvax 1 Dose / Vial Childhood Meningococcal ACYW-135 Vaccine

Brand Name : Walvax

Model Number : Group ACYW-135 Meningococcal Polysaccharide Vaccine

Certification : Certificated by China/Indonesia

Place of Origin : China

Payment Terms : L/C, T/T

Delivery Time : In stock: 20 workdays; To be produced: 4 months

Packaging Details : Vial, 1 dose. Each lyophilized vaccine is accompanied with 1 vial of 0.5ml diluent.

Prsentation : Lyophilized, 1 single human dose/vial, 0.5 ml/dose after reconstitution

Eligibles : Children of 2 years old of age and above

Schedule : ≥2 years: 1 dose, inject subcutaneously into lateral upper arm

Shelf Life : 24 months at 2-8℃

Package : 1ml, vial. Each vial of lyophilized vaccine is accompanied with one vial of 0.5ml diluent

Dosage Form : Vial

Contact Now

1) Menigococcal Disease

① What is meningococcal disease?

Meningococcal disease is caused by infection with bacteria called Neisseria meningitidis which can be found normally in people’s throats and noses. These bacteria can infect the tissue (the “meninges”) that surrounds the brain and spinal cord and cause meningitis, or they may infect the blood or other body organs.

Signs and symptoms of meningococcal disease include sudden onset of fever, stiff neck, headache, nausea, vomiting, sensitivity to light and/or mental confusion. A rash may also be present. Changes in behavior such as confusion, sleepiness, and unresponsiveness are important symptoms of illness.

Onset of illness may be very sudden, and 10-15% die despite receiving antibiotic treatment. Of those who survive, 10-20% may lose limbs, become hearing impaired or deaf, have problems with their nervous system, including long-term neurologic problems, or have seizures or strokes.


② How common is meningococcal disease?

Worldwide, the incidence of meningococcal disease is highest in a region of sub-Saharan African known as the “meningitis belt”. This hyper-endemic region extends from Senegal to Ethiopia, and is characterized by seasonal epidemics during the dry season (incidence rate: 10-100 cases per 100,000 population), punctuated by explosive epidemics in 8-12 year cycles (incidence rates can be greater than 1,000 cases per 100,000 population).

Across the meningitis belt, at least 350 million people are at risk for meningitis during these annual epidemics. Meningitis epidemics are generally caused by serogroup A, although outbreaks have also been caused by serogroups C, W135, and X (1-3, 7, 13, 21, 28) of Neisseria meningitidis.


What is serogroup of Neisseria meningitidis?

Neisseria meningitidis may either be encapsulated or unencapsulated. However, nearly all invasive Neisseria meningitidis organisms are encapsulated, or surrounded by a polysaccharide capsule.

This capsular polysaccharide is used to classify Neisseria meningitidis into 12 serogroups. Six of these serogroups cause the great majority of infections in people: A, B, C, W135, X, and Y.


How to prevent meningococcal disease?

Vaccination is one of the most effective ways to prevent meningococcal disease and Walvax’s Group ACYW-135 Meningococcal Polysaccharide Vaccine has been introduced to Indonesian Government since 2017 which is mainly used for Muslims going for pilgrimage.

2) Overseas Sales

1.5 million: Walvax has exported more than 1.5 million doses of Group ACYW-135 Meningococcal Polysaccharide Vaccine since 2017

17+ Countries: Exported to 7 countries in Asia and Africa

More than 10 countries under import registration process

Keeping on expanding the international market

Muslim Pilgrimage: A certain of Group ACYW-135 Meningococcal Polysaccharide Vaccine, a must for muslim pilgrimage. Walvax Group ACYW-135 Meningococcal Polysaccharide Vaccine is MUI HALAL certified and already protected more than 1 million Muslim pilgrims.

WHO-PQ: Men ACYW-135 Polysaccharide Vaccine is now under World Health Organization (WHO) prequalification process which is expected to pass by 2021

3) Prescribing Information

Product name

Group ACYW-135 Meningococcal Polysaccharide Vaccine

Composition

1 dose contains:

Group A Meningococcal Polysaccharide…………………….50μg

Group C Meningococcal Polysaccharide…………………….50μg

Group Y Meningococcal Polysaccharide…………………….50μg

Group W135 Meningococcal Polysaccharide………………..50μg

Lactose……………………………………………………...........4mg

Sodium Chloride………………………………………..…….4.25mg

Diluent: Sterile water for injection……………………………0.5ml

Presentation

Lyophilized, 1 single human dose/vial, 0.5 ml/dose after reconstitution.

Schedule

≥2 years: 1 dose, inject subcutaneously into lateral upper arm.

Shelf Life

24 months at 2-8℃.



Product Tags:

Childhood Meningococcal ACYW-135 Vaccine

      

1 Dose / Vial Meningococcal ACYW-135 Vaccine

      

Walvax Meningococcal Meningitis Vaccine

      
Quality Walvax 1 Dose / Vial Childhood Meningococcal ACYW-135 Vaccine for sale

Walvax 1 Dose / Vial Childhood Meningococcal ACYW-135 Vaccine Images

Inquiry Cart 0
Send your message to this supplier
 
*From:
*To: Walvax Biotechnology Co., Ltd.
*Subject:
*Message:
Characters Remaining: (0/3000)